Early molecular response in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with dasatinib (DAS) or imatinib (IM) from DASISION.

7055Background: An exploratory landmark analysis from DASISION demonstrated improved PFS and OS in newly diagnosed CML-CP pts treated with DAS or IM who achieved BCR-ABL1 ≤ 10% at 3 mo, a milestone...